European Journal of Heart Failure

OCTOBER 9, 2023

Impact of COVID-19 in patients with HF and mildly reduced and preserved ejection fraction. COVID-19, coronvirus disease-2019; HF, heart failure. Aim COVID-19 may affect clinical risk in patients with heart failure. DELIVER began before and was conducted during the COVID-19 pandemic.

Preserved Ejection Fraction 40

Preserved Ejection Fraction COVID-19 Heart Failure Hospital 40

European Journal of Heart Failure

MARCH 4, 2024

Patients with heart failure and mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) have a high risk of developing LRTI. Prior studies were able to show that sodium–glucose cotransporter 2 inhibitors may reduce the incidence of LRTI in patients with type 2 diabetes.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure COVID-19 Kidney Disease 40

Cardiovascular Diabetology

AUGUST 15, 2024

Patients with diabetes have an increased risk of developing heart failure with preserved ejection fraction (HFpEF). This study aimed to compare indices of myocardial deformation and perfusion between patients.

Preserved Ejection Fraction 52

Preserved Ejection Fraction Heart Failure Diabetes Research 52

American College of Cardiology

APRIL 10, 2024

What are the effects of semaglutide across a broad range of outcomes in people with obesity-related heart failure with preserved ejection fraction (HFpEF) with and without diabetes, and consistency across key patient subgroups?

Preserved Ejection Fraction 60

Preserved Ejection Fraction Obesity Heart Failure Diabetes 60

American College of Cardiology

JUNE 24, 2024

Semaglutide reduces body weight to a greater extent in women with obesity-related heart failure with preserved ejection fraction (HFpEF) than in men, and improved Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS) to the same extent in both women and men, according to results from a prespecified secondary analysis of pooled (..)

Preserved Ejection Fraction 65

Preserved Ejection Fraction Obesity Heart Failure Cardiomyopathy 65

Open Heart

NOVEMBER 27, 2023

Introduction This study aimed to evaluate the use and dose of loop diuretics (LDs) across the entire ejection fraction (EF) spectrum in a large, ‘real-world’ cohort of chronic heart failure (HF) patients. Among all LDs users, the median FDE was 40 mg (IQR: 40–80).

Heart Failure 52

Heart Failure Preserved Ejection Fraction Outpatient Diabetes 52

Cardiometabolic Health Congress

JULY 25, 2023

There are significant data that show that if you have obesity, you have a high risk of developing coronary heart disease, heart failure, type 2 diabetes (T2D) or risk factors such as hypertension and dyslipidemia. [1] Is the obesity paradox a real phenomenon?

Obesity 52

Obesity BMI Heart Failure Cardiovascular Disease 52

European Journal of Heart Failure

FEBRUARY 4, 2024

Abstract Aim Pathophysiological differences between patients with heart failure with preserved (HFpEF) and reduced (HFrEF) ejection fraction (EF) remain unclear. Study design and main study results. In HFrEF, interleukin (IL)-8 and IL-6 were possible targets related to lower EF and worsening renal function.

Preserved Ejection Fraction 40

Preserved Ejection Fraction Heart Failure Biomarkers Diabetes 40

DAIC

FEBRUARY 29, 2024

12:15 p.m.

Aortic valve 103

Aortic valve Myocardial Infarction Aortic Blood Pressure 103

CardiacWire

AUGUST 2, 2024

Lilly’s blockbuster GLP-1 tirzepatide appears poised to become the next major HFpEF drug, after topline results from the SUMMIT trial showed that it significantly improved both outcomes and symptoms among patients with heart failure with preserved ejection fraction and obesity. vs. +15 KCCQ-CSS points).

Outcomes 59

Outcomes Preserved Ejection Fraction Heart Failure Obesity 59

DAIC

JUNE 26, 2024

Getty Images milla1cf Wed, 06/26/2024 - 18:59 June 26, 2024 — Semaglutide , a medication initially developed for type 2 diabetes and obesity, significantly improves symptoms in men and women with a common type of heart failure that has had few therapeutic options.

Preserved Ejection Fraction 105

Preserved Ejection Fraction Obesity BMI Heart Failure 105

Cardiology Update

APRIL 9, 2024

Investigators assessed if empagliflozin could lower the risk of hospitalization for heart failure (HF) or death from cardiovascular disease (CVD). STEP-HFpEF DM 5 ( NCT04916470 ) explored the effects of semaglutide in obesity-related HF with preserved ejection fraction (HFpEF) and type 2 diabetes.

Angina 52

Angina Myocardial Infarction Aortic valve Coronary Artery Disease 52